Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry

Journal of Immunological Methods

Volumn 417, Issue , 2015, Pages 22-33

  Kagina, Benjamin M ^a,b   Mansoor, Nazma ^a,c   Kpamegan, Eloi P ^d   Penn Nicholson, Adam ^a   Nemes, Elisa ^a   Smit, Erica ^a   Gelderbloem, Sebastian ^e   Soares, Andreia P ^a,b   Abel, Brian ^a,f   Keyser, Alana ^a   Sidibana, Mzwandile ^a   Hughes, Jane E ^a   Kaplan, Gilla ^g,h   Hussey, Gregory D ^a,b   Hanekom, Willem A ^a   Scriba, Thomas J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BD Biosciences   (South Africa)

^d AERAS   (United States)

^e Aeras   (South Africa)

^f AGENCY FOR SCIENCE   (Singapore)

^g PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Flow cytometry; Intracellular cytokine staining assay; Qualification; Whole blood

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; MITOGENIC AGENT; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL ANTIGEN; BCG VACCINE; CYTOKINE; IL2 PROTEIN, HUMAN;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TH1 CELL; BLOOD; IMMUNOLOGY; MYCOBACTERIUM BOVIS; PROCEDURES; STAINING; TUBERCULOSIS, PULMONARY;

CORYNEBACTERINEAE;

ADULT; ANTIGENS, BACTERIAL; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CRYOPRESERVATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; LIMIT OF DETECTION; MYCOBACTERIUM BOVIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923029140     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.12.003     Document Type: Article

References (22)

1. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., Makhethe L., Erasmus M., de Kock M., van der Merwe L., et al. The novel tuberculosis vaccine, Aeras-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J. Respir. Crit. Care Med. 2010, 181:1407.
2. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., Halloran M.E. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13980.
3. Corrigal J. Western Cape Provincial EPI Vaccination Survey [(accessed 16 September 2014)]. http://www.capegateway.gov.za/Text/2007/6/cd_volume_7_childhood_diseases_overview.pdf.
4. Day C.L., Tameris M., Mansoor N., van Rooyen M., de Kock M., Geldenhuys H., Erasmus M., Makhethe L., Hughes E.J., Gelderbloem S., et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am. J. Respir. Crit. Care Med. 2013, 188:492.
5. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu. Rev. Public Health 2013, 34:271.
6. Evans T.G., Brennan M.J., Barker L., Thole J. Preventive vaccines for tuberculosis. Vaccine 2013, 31(Suppl. 2):B223.
7. (FDA) FaDA Guidance for Industry: Q2b Validation of Analytical Procedures: Methodology 1996, Food and Drug Administration (FDA).
8. Hanekom W.A., Hughes J., Mavinkurve M., Mendillo M., Watkins M., Gamieldien H., Gelderbloem S.J., Sidibana M., Mansoor N., Davids V., et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J. Immunol. Methods 2004, 291:185.
9. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., Weichold F.F., Hoft D.F., Parida S.K., Fruth U.J. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med. 2008, 5:e145.
10. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., Lang T., Veldsman A., Hatherill M., Merwe L.v.d., Fletcher H.A., Mahomed H., Hill A.V.S., Hanekom W.A., Hussey G.D., McShane H. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. The Journal of Infectious Diseases 2008, 198:544.
11. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., Shen F., Eaton S.M., Gaffen S.L., Swain S.L., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 2007, 8:369.
12. Mazurek G.H., Jereb J., Vernon A., LoBue P., Goldberg S., Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm. Rep. 2010, 59:1.
13. Nomura L.E., Walker J.M., Maecker H.T. Optimization of whole blood antigen-specific cytokine assays for CD4+ T cells. Cytometry 2000, 40:60.
14. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A., Brittain N.J., Williams N., Rowland-Jones S., Hill A.V., Adegbola R.A., et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Transl. Med. 2011, 3:88ra56.
15. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., Keyser A., Moyo S., Brittain N., Lawrie A., Gelderbloem S., Veldsman A., Hatherill M., Hawkridge A., Hill A.V., Hussey G.D., Mahomed H., McShane H., Hanekom W.A. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40:279.
16. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Mauff K., Hughes E.J., Moyo S., Brittain N., Lawrie A., et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J. Infect. Dis. 2011, 203:1832.
17. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., Mauff K., Moyo S., Brittain N., Lawrie A., Mulenga H., de Kock M., Makhethe L., Janse van Rensburg E., Gelderbloem S., Veldsman A., Hatherill M., Geldenhuys H., Hill A.V., Hawkridge A., Hussey G.D., Hanekom W.A., McShane H., Mahomed H. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769.
18. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., Shea J.E., McClain J.B., Hussey G.D., Hanekom W.A., Mahomed H., McShane H. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021.
19. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhoodtuberculous meningitis and miliary tuberculosis worldwide: a metaanalysisand assessment of cost-effectiveness. Lancet 2006, 367:1173.
20. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., Nouta J., Klein M.R., Rosenkrands I., Ottenhoff T.H., et al. Ag85b-Esat-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571.
21. Weinberg A., Zhang L., Brown D., Erice A., Polsky B., Hirsch M.S., Owens S., Lamb K. Viability and functional activity of cryopreserved mononuclear cells. Clin. Diagn. Lab. Immunol. 2000, 7:714.
22. World Health Organization Global Tuberculosis Report 2013.